Product Description
Mechanisms of Action: GPIIb/IIIa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Other|Scleroderma, Diffuse|Raynaud Disease
Phase 1: Healthy Volunteers|Acute Coronary Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02419820 |
ID-TMG-102 | P1 |
Terminated |
Acute Coronary Syndrome |
2016-04-01 |
2024-10-16 |
Primary Endpoints |
|
NCT00619931 |
APD791-002 | P1 |
Completed |
Healthy Volunteers |
2008-06-01 |
2024-10-16 |
Primary Endpoints |
|
NCT00529646 |
APD791-001 | P1 |
Completed |
Healthy Volunteers |
None |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT04915950 |
APD791-204 | P2 |
Terminated |
Scleroderma, Diffuse|Raynaud Disease |
2022-09-02 |
23% |
2024-10-16 |
Primary Endpoints|Treatments |
NCT04848220 |
APD791-202 | P2 |
Terminated |
Other |
2022-08-23 |
12% |
2024-10-16 |
Primary Endpoints |
2020-000238-16 |
2020-000238-16 | P2 |
Terminated |
Unknown |
2022-08-23 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/11/2022 |
News Article |
Pfizer Completes Acquisition of Arena Pharmaceuticals |
|
02/23/2022 |
News Article |
Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates |
|
12/13/2021 |
News Article |
Pfizer to Acquire Arena Pharmaceuticals |
|
11/04/2021 |
News Article |
Arena Reports Third Quarter Financial Results and Key Program Updates |